Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya Khalil

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Scientific Reports|November 19, 2016
Gene expression profiling of breast cancer in Lebanese womenJoelle Makoukji, Nadine J Makhoul, Maya Khalil, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Patient-Derived Three-Dimensional Lung Tumor Models to Evaluate Response to ImmunotherapyKayla F Goliwas, Kenneth P Hough, Sruti Sivan, et al.
NPJ Precision Oncology|March 1, 2026
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumorsGerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2017
Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective AnalysisArafat Tfayli, Hind Rafei, Alain Mina, et al.
NPJ Precision Oncology|June 16, 2026
Patient-derived three-dimensional lung tumor models to evaluate response to therapyKayla F Goliwas, Aakash Desai, Kenneth P Hough, et al.
JCO Precision Oncology|June 12, 2024
Talazoparib in Patients With Solid Tumors With <i>BRCA1</i>/<i>2</i> Mutation: Results From the Targeted Agent and Profiling Utilization Registry StudyGordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesotheliomaAaron S Mansfield, Jun Vivien Yin, Penelope Bradbury, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 13, 2021
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyApar Kishor P Ganti, Billy W Loo, Michael Bassetti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026Apar Kishor P Ganti, Billy W Loo, Shahed Badiyan, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Scientific Reports|November 19, 2016
Gene expression profiling of breast cancer in Lebanese womenJoelle Makoukji, Nadine J Makhoul, Maya Khalil, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
Patient-Derived Three-Dimensional Lung Tumor Models to Evaluate Response to ImmunotherapyKayla F Goliwas, Kenneth P Hough, Sruti Sivan, et al.
NPJ Precision Oncology|March 1, 2026
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumorsGerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2017
Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective AnalysisArafat Tfayli, Hind Rafei, Alain Mina, et al.
NPJ Precision Oncology|June 16, 2026
Patient-derived three-dimensional lung tumor models to evaluate response to therapyKayla F Goliwas, Aakash Desai, Kenneth P Hough, et al.
JCO Precision Oncology|June 12, 2024
Talazoparib in Patients With Solid Tumors With <i>BRCA1</i>/<i>2</i> Mutation: Results From the Targeted Agent and Profiling Utilization Registry StudyGordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesotheliomaAaron S Mansfield, Jun Vivien Yin, Penelope Bradbury, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 13, 2021
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyApar Kishor P Ganti, Billy W Loo, Michael Bassetti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026Apar Kishor P Ganti, Billy W Loo, Shahed Badiyan, et al.
Pageof 3